The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.
0.01M PBS, pH 7.4.
Research Grade Sotigalimab Biosimilar
Tumor necrosis factor receptor superfamily member 5,B-cell surface antigen CD40,Bp50,CD40L receptor,TNFRSF5,CDw40,CD40
Protein A or G purified from cell culture supernatant.
Please contact with the lab for this information.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6
For research use only. Not suitable for clinical or therapeutic use.
武汉科斯坦生物科技有限公司 版权所有(C)2023 XML 技术支持： 食品商务网 盖德化工网